Indian drugmaker Dr Reddy's posts quarterly profit slump

Dr Reddy's reported an 86% slump in quarterly profit, pressured by pricing competition in its key U.S. market. The results point to weaker profitability and ongoing margin headwinds for the Indian drugmaker. The news is likely to weigh on the stock, though the impact is mainly company-specific rather than sector-wide.

Analysis

Dr Reddy's reported an 86% slump in quarterly profit, pressured by pricing competition in its key U.S. market. The results point to weaker profitability and ongoing margin headwinds for the Indian drugmaker. The news is likely to weigh on the stock, though the impact is mainly company-specific rather than sector-wide.